Phase 1Completed

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Sponsor
I-Mab Biopharma US Limited (Industry)
Enrollment
98 enrolled
Conditions
Solid Tumor; Lymphoma
Interventions
TJ011133; Pembrolizumab; Rituximab
Ages
adults, older adults
Registry
NCT03934814

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Primary outcomes

  • Dose Limiting Toxicities (DLT)
  • Incidence and Severity of Adverse Events
  • Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy
  • Change in Eastern Cooperative Oncology Group (ECOG) Performance Status

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started